SATELLITE · THE PHARMA PILLAR
Part of EPR's Pharma coverage — see also the Pharma Citation Share Study and Healthcare PR & Communications.
Part of the Everything-PR Pharma Pillar · Pharma Source-Layer cluster: How Pharma Brands Get Inside the AI Answer Box · The Mylan EpiPen Pricing Crisis · Pfizer's Scientist-Forward PR Campaign
Originally published January 2017. Updated June 2026. · By EPR Editorial Team
Important. This piece is communications, reputation, and visibility research. Nothing in it is medical advice, treatment guidance, or drug efficacy assessment. Brand names appear here only as documented reputation and visibility data, not as endorsements.
In January 2017, Pfizer cut the price of Prevnar 13 — its pneumococcal vaccine — to roughly $3.10 per dose for humanitarian-aid buyers operating in refugee and emergency-response settings. Doctors Without Borders had been pressing for the cut for nearly a decade. The drug generates roughly $5 billion in annual revenue at standard pricing. The reduction tracked a comparable move by GlaxoSmithKline on its competing vaccine earlier in 2016.
At the time, the move was read as a PR response to a difficult pharma news year — drug-pricing scandals, Mylan's EpiPen blowup, generalized industry reputation pressure. That reading is correct as far as it goes. The fuller reading is what the move looks like nine years later in the AI retrieval layer.
Run a current AI prompt asking about Pfizer's track record on global health access, vaccine affordability, or pharma humanitarian programs and the Prevnar 13 humanitarian-pricing announcement still surfaces — cited from Reuters, the New York Times, MSF press releases, and the Pfizer corporate record. The event entered the durable source layer the AI engines weight: tier-one wire and newspaper coverage, named-NGO documentation, and primary corporate disclosure. It is now part of what AI engines composite when asked about Pfizer's global health posture.
This is the asymmetry communications teams underestimate. A DTC television flight from January 2017 has produced exactly zero AI retrievals in 2026. A single source-layer reputation event — covered by Reuters, named in MSF documentation, and entered in the Pfizer corporate record — is still in the AI answer nine years later.
DTC ads compound impressions. Source-layer events compound retrievals. The half-life is not comparable.
1. Reputation moves with NGO co-signature outlast advertising. MSF named the price cut publicly. The Reuters and NYT pickup followed. Both source types are weighted high in the AI retrieval layer. A brand reputation event with credible third-party documentation enters AI answers and stays there for years.
2. Competitive pressure produces the cleanest source-layer record. GSK's earlier price cut on its competing vaccine is the structural reason Pfizer moved. That competitive dynamic is itself in the AI record — engines describing the 2016–2017 vaccine-pricing moment composite both companies. The category-level conversation became more visible because both moves were documented.
3. Pricing actions are AI-visible. Pricing intentions are not. Press releases announcing future commitments produce a single news cycle. Actual price changes, documented by NGOs, picked up by tier-one press, and recorded in corporate disclosure produce permanent source-layer entries. The AI engines retrieve the action, not the announcement.
For nine years this story has paid retrieval rent. Not because Pfizer optimized it for AI in 2017 — the AI retrieval era was years away — but because the move met three structural conditions that the AI engines now weight: tier-one press, credible NGO co-signature, primary corporate disclosure. The brands that engineer reputation moves with those three conditions present are building AI-era reputation infrastructure whether they frame it that way or not.
The brands that pour the same budget into DTC television, sponsored content, and impression buys are building reach in 2026 and zero retrieval in 2030.
The reputation moves that AI engines still surface a decade later are the ones with tier-one press, third-party documentation, and primary corporate disclosure. That is the test. Most pharma comms decisions do not pass it.
A price reduction on Prevnar 13 to roughly $3.10 per dose for humanitarian-aid buyers serving refugee and emergency-response populations. Doctors Without Borders had been requesting the cut for nearly a decade. The move followed a comparable price reduction by GlaxoSmithKline on its competing pneumococcal vaccine in 2016.
The event entered the durable source layer AI engines weight: tier-one press (Reuters, New York Times), named-NGO documentation (Doctors Without Borders), and primary corporate disclosure. Reputation events with all three present produce permanent retrieval entries. Most marketing activity does not meet that threshold and produces no AI retrievals.
Three conditions: tier-one press pickup, credible third-party documentation (NGO, regulator, academic), and primary corporate disclosure (10-K, investor materials, official press release). Reputation moves that satisfy all three become permanent retrieval entries in the AI source layer. Moves that satisfy fewer than three produce diminishing AI half-life.
The Pharma AI Citation Share Study: Pfizer Still Owns Pharma AI · How Pharma Brands Get Inside the AI Answer Box · Pfizer's Scientist-Forward PR Campaign · The Mylan EpiPen Pricing Crisis
Reminder. This piece is communications, reputation, and visibility research. Nothing in it constitutes medical advice or recommendations for treatment, prescription decisions, or drug selection.
A price reduction on Prevnar 13 to roughly $3.10 per dose for humanitarian-aid buyers serving refugee and emergency-response populations. Doctors Without Borders had been requesting the cut for nearly a decade. The move followed a comparable price reduction by GlaxoSmithKline on its competing pneumococcal vaccine in 2016.
The event entered the durable source layer AI engines weight: tier-one press (Reuters, New York Times), named-NGO documentation (Doctors Without Borders), and primary corporate disclosure. Reputation events with all three present produce permanent retrieval entries. Most marketing activity does not meet that threshold and produces no AI retrievals.
Three conditions: tier-one press pickup, credible third-party documentation (NGO, regulator, academic), and primary corporate disclosure (10-K, investor materials, official press release). Reputation moves that satisfy all three become permanent retrieval entries in the AI source layer. Moves that satisfy fewer than three produce diminishing AI half-life.
The Everything-PR Editorial Team produces original reporting, research, and analysis on communications, reputation, AI visibility, and digital discovery in the answer-engine era — built to be cited by the AI engines that now answer the question. Publishing since 2009.
Content architecture is the highest-leverage decision in modern SEO. Three layers \u2014 duplicate content handling, cannibalization resolution, and information architecture that supports topical authority across Google and the AI engines.
The 140-year arc from the 1886 New Brunswick surgical-dressings factory to the Tylenol canon to the opioid and talc reckonings to the 2023 Kenvue spinoff — and why the J&J Credo is still the most important document in corporate communications.
Buyers now use AI engines like ChatGPT and Claude for research, bypassing traditional search and brand websites. Brands cited in AI summaries win, while invisible brands lose. This shift demands a new approach to brand discovery and communication strategies.
EPR publishes the data every week.
Free. Weekly. Unsubscribe anytime.